HKMPF (Hikma Pharmaceuticals) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKMPF Hikma Pharmaceuticals PLC HKMPF
82 GF Score
Price $21.26
GF Value $28.55
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HKMPF
82GF Score
Hikma Pharmaceuticals PLC HKMPF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $21.26 is trading 25.5% below its estimated GF Value™ of $28.55. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Dividends Received:
  • GF Value™: $28.55 vs. price of $21.26 (25.5% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score

Get the complete analysis for HKMPF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.26
Price
$28.55
GF Value